Naftidrofuryl

Naftidrofuryl, also known as nafronyl and sold under the brand name Praxilene among others, is a serotonin 5-HT 2 receptor antagonist which is used as a vasodilator in the treatment of peripheral and cerebral vascular disorders.

Uses your system voice; voice and rate in settings.

≈ 2 min read

Cite, export and learn8 citation formats · 8 exports · lesson and quiz

Names in other languages

No names in other languages are held for this entry yet.

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

Naftidrofuryl, also known as nafronyl and sold under the brand name Praxilene among others, is a serotonin 5-HT 2 receptor antagonist which is used as a vasodilator in the treatment of peripheral and cerebral vascular disorders. It is taken orally.

Medical uses

Naftidrofuryl is used as a vasodilator in the treatment of peripheral and cerebral vascular disorders. It is also licensed for the treatment of intermittent claudication due to peripheral arterial disease. Historically, it has been used to treat sudden idiopathic hearing loss and acute tinnitus. Naftidrofuryl may be effective for relieving the pain of muscle cramps.

Adverse effects

Naftidrofuryl has been associated with nausea, abdominal pain, and rash. Rarely, hepatitis and liver failure have been reported.

Pharmacodynamics

Naftidrofuryl acts as a selective antagonist of 5-HT 2 receptors (with action as an inverse agonist of the 5-HT 2A receptor specifically characterized).

Pharmacokinetics

The oral bioavailability of naftidrofuryl is 20 to 78% in different studies. Its time to peak levels is 0.8 to 1.0 hours. There is some evidence that naftidrofuryl crosses the blood–brain barrier and penetrates into the central nervous system.

The drug's plasma protein binding is 80%. It is metabolized in the liver. The elimination half-life of naftidrofuryl is 1.2 to 2 hours.

Its half-life is longer in the elderly than in younger people. The drug's duration of effects is 2 to 3 hours and closely parallels circulating levels of naftidrofuryl.

History

Naftidrofuryl was first described in the scientific literature by at least 1966.

Names

Naftidrofuryl is the generic name of the drug and its ( , , , and . It is also known as naftidrofurile ( ) or as nafronyl ( . Naftidrofuryl is marketed under a variety of trade names, including Artocoron, Azunaftil, Di-Actane, Dusodril, Enelbin, Frilix, Gevatran, Iridus, Iridux, Luctor, Nafti, Naftilong, Naftodril, Nafoxal, Praxilene, Sodipryl Retard, Stimlor, and Vascuprax, among others.

Availability

Naftidrofuryl is marketed and used widely throughout the world.

Text derived from https://en.wikipedia.org/w/index.php?oldid=1362588562 under CC BY-SA 4.0; modifications have been made.

Words in each sectionPharmacokineticsPharmacokineticsPharmacokinetics: 98 words98Medical usesMedical usesMedical uses: 55 words55NamesNamesNames: 52 words52AvailabilityAvailabilityAvailability: 30 words30PharmacodynamicsPharmacodynamicsPharmacodynamics: 23 words23Adverse effectsAdverse effectsAdverse effects: 18 words18HistoryHistoryHistory: 12 words12
Words in each section. Measured from the stored article body; sections below the minimum are not plotted.

Provenance

snapshot enwiki-001362588562 · captured 2026-07-04 · ledger · version history

Cite this page as: encyclopegia.org, “Naftidrofuryl”, snapshot enwiki-001362588562. https://encyclopegia.org/a/naftidrofuryl

Sources cited in this revision

7 named source(s) extracted from the cited revision. A source with no author is shown by its publication; nothing is invented.